FAM194A Inhibitors
FAM194A inhibitors encompass a variety of chemical compounds that suppress the functional activity of FAM194A through diverse signaling pathways and cellular processes. The inhibition of cyclin-dependent kinases (CDKs) by PD 0332991, Olomoucine, and Roscovitine results in cell cycle arrest at the G1 phase, which is likely to decrease the activity of FAM194A by reducing cell proliferation, a process in which FAM194A may play a part. Similarly, the impediment of histone deacetylases by Trichostatin A changes the transcriptional landscape and chromatin structure, which could lead to a reduction in FAM194A expression. The mTOR pathway, an important regulator of cell growth, when inhibited by Rapamycin, is expected to diminish FAM194Aactivity due to the role of mTOR in cell proliferation and survival. Moreover, PI3K inhibitors such as LY 294002 and Wortmannin suppress the AKT signaling pathway, which is implicated in cell survival and growth, and thus, can indirectly decrease FAM194A activity.
In the same vein, the MAPK pathway serves as a target for several inhibitors that in turn affect FAM194A function. U0126 and PD 98059, both MEK inhibitors, hinder the MAPK/ERK pathway, potentially leading to a reduction in FAM194A activity by influencing cell cycle progression and cell growth. JNK inhibition by SP600125, and p38 MAPK inhibition by SB 203580, are likely to decrease FAM194A activities by impacting cellular processes like apoptosis and cell differentiation, and stress responses, respectively. The broad-spectrum protein kinase inhibition by Staurosporine might also diminish FAM194A's functional activity by altering various signaling pathways in which FAM194A is involved. Collectively, these inhibitors employ distinct yet converging pathways to reduce the functional activity of FAM194A, thereby highlighting the complex regulatory networks that govern its role in cellular physiology.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
PD 0332991 is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Inhibition of these kinases can lead to cell cycle arrest at the G1 phase, which may diminish the functional activity of FAM194A by limiting cell proliferation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that promotes acetylation of histones, leading to open chromatin and affecting gene expression. This can indirectly diminish FAM194A expression by altering transcriptional regulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that impedes cell growth and proliferation by inhibiting the mTOR pathway. Since FAM194A may be involved in these processes, rapamycin can indirectly lead to decreased FAM194A activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a phosphoinositide 3-kinase (PI3K) inhibitor that can suppress the AKT signaling pathway, which is involved in cell survival and growth. This inhibition can indirectly lead to decreased FAM194A activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor that can inhibit multiple kinases involved in cell signaling, potentially diminishing FAM194A's functional activity by affecting signal transduction pathways it is involved in. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are part of the MAPK/ERK pathway. By inhibiting this pathway, U0126 can indirectly lead to decreased FAM194A activity as it affects cell cycle progression and growth, where FAM194A may be implicated. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an MEK inhibitor, potentially lcausing decreased FAM194A activity by inhibiting the MAPK/ERK pathway, which is involved in cell proliferation and survival. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathway. By inhibiting JNK, SP600125 can indirectly lead to decreased FAM194A activity by affecting apoptosis and cell differentiation processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 MAPK can lead to altered cell stress responses and cytokine production, which can indirectly diminish the functional activity of FAM194A. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible PI3K inhibitor that can lead to decreased AKT activation. This inhibition can indirectly lead to decreased FAM194A activity by affecting cell survival and proliferation pathways. | ||||||